Literature DB >> 10728030

Applications of anti-platelet monitoring in catheterization laboratory.

D Mukherjee1, D J Moliterno.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10728030     DOI： 10.1023/a:1018724827741

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  44 in total

1.  Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

Authors:  E J Topol; J J Ferguson; H F Weisman; J E Tcheng; S G Ellis; N S Kleiman; R J Ivanhoe; A L Wang; D P Miller; K M Anderson; R M Califf
Journal:  JAMA       Date:  1997-08-13       Impact factor: 56.272

2.  Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.

Authors:  M Gawaz; A Ruf; F J Neumann; G Pogátsa-Murray; T Dickfeld; D Zohlnhöfer; A Schömig
Journal:  Thromb Haemost       Date:  1998-12       Impact factor: 5.249

3.  An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia.

Authors:  A T Nurden; J P Caen
Journal:  Br J Haematol       Date:  1974-10       Impact factor: 6.998

4.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

Authors: 
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

5.  Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.

Authors:  S R Steinhubl; K Kottke-Marchant; D J Moliterno; M L Rosenthal; N K Godfrey; B S Coller; E J Topol; A M Lincoff
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

6.  Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.

Authors:  H K Gold; L W Gimple; T Yasuda; R C Leinbach; W Werner; R Holt; R Jordan; H Berger; D Collen; B S Coller
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

7.  Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.

Authors:  N S Kleiman; A E Raizner; R Jordan; A L Wang; D Norton; K F Mace; A Joshi; B S Coller; H F Weisman
Journal:  J Am Coll Cardiol       Date:  1995-12       Impact factor: 24.094

8.  Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation.

Authors:  B S Coller; K T Springer; L E Scudder; J L Kutok; M Ceruso; G D Prestwich
Journal:  J Biol Chem       Date:  1993-10-05       Impact factor: 5.157

Review 9.  Platelet GPIIb-IIIa blockers.

Authors:  E J Topol; T V Byzova; E F Plow
Journal:  Lancet       Date:  1999-01-16       Impact factor: 79.321

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321
View more
  2 in total

1.  Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.

Authors:  D Mukherjee; D P Chew; M Robbins; J S Yadav; R E Raymond; D J Moliterno
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

Review 2.  Monitoring antiplatelet therapy: What is the best method?

Authors:  D Mukherjee; D J Moliterno
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.